MX2014013367A - Composiciones organicas para tratar enfermedades relacionadas con kras. - Google Patents
Composiciones organicas para tratar enfermedades relacionadas con kras.Info
- Publication number
- MX2014013367A MX2014013367A MX2014013367A MX2014013367A MX2014013367A MX 2014013367 A MX2014013367 A MX 2014013367A MX 2014013367 A MX2014013367 A MX 2014013367A MX 2014013367 A MX2014013367 A MX 2014013367A MX 2014013367 A MX2014013367 A MX 2014013367A
- Authority
- MX
- Mexico
- Prior art keywords
- lung
- related diseases
- cancer
- kras
- syndrome
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641588P | 2012-05-02 | 2012-05-02 | |
| PCT/US2013/038847 WO2013166004A2 (en) | 2012-05-02 | 2013-04-30 | Organic compositions to treat kras-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014013367A true MX2014013367A (es) | 2014-12-08 |
Family
ID=48366565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013367A MX2014013367A (es) | 2012-05-02 | 2013-04-30 | Composiciones organicas para tratar enfermedades relacionadas con kras. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20150238515A1 (enExample) |
| EP (3) | EP2844757A2 (enExample) |
| JP (1) | JP2015517466A (enExample) |
| KR (1) | KR20150004414A (enExample) |
| CN (2) | CN104583406A (enExample) |
| AU (5) | AU2013256471A1 (enExample) |
| BR (1) | BR112014027337A2 (enExample) |
| CA (2) | CA2872304C (enExample) |
| EA (1) | EA201492004A1 (enExample) |
| HK (1) | HK1206387A1 (enExample) |
| MX (1) | MX2014013367A (enExample) |
| WO (1) | WO2013166004A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620525A (zh) * | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
| US10278991B2 (en) | 2014-05-14 | 2019-05-07 | Targimmune Therapeutics Ag | Polyethyleneimine polyethyleneglycol vectors |
| US11180759B2 (en) * | 2016-01-19 | 2021-11-23 | The University Of North Carolina At Chapel Hill | Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS |
| US10858656B2 (en) * | 2016-04-01 | 2020-12-08 | Avidity Biosciences, Inc. | KRAS nucleic acids and uses thereof |
| KR102775461B1 (ko) | 2016-04-01 | 2025-02-28 | 어비디티 바이오사이언시스 인크. | 핵산-폴리펩타이드 조성물 및 이의 용도 |
| KR102543645B1 (ko) * | 2016-07-20 | 2023-06-16 | 주식회사 지씨지놈 | 유전성 발달장애 진단용 조성물 및 이의 용도 |
| CN118638787A (zh) | 2017-12-06 | 2024-09-13 | 艾维迪提生物科学公司 | 治疗肌萎缩和强直性肌营养不良的组合物和方法 |
| CN113993521A (zh) * | 2019-06-05 | 2022-01-28 | 南方研究院 | 基于噻拉滨和噻拉滨前药的治疗 |
| US12146139B2 (en) * | 2019-11-14 | 2024-11-19 | The Board Of Regents Of The University Of Oklahoma | Oligonucleotide interference treatments of prostate cancer |
| TW202144572A (zh) | 2020-03-19 | 2021-12-01 | 美商亞維代堤生物科學公司 | 治療臉肩胛肱骨肌肉失養症之組合物及方法 |
| JP7839554B2 (ja) * | 2020-04-07 | 2026-04-02 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物 |
| WO2023034537A1 (en) * | 2021-09-02 | 2023-03-09 | Molecular Axiom, Llc | Compositions and methods for modulating kras expression |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| JP2026503133A (ja) * | 2023-01-18 | 2026-01-27 | モレキュラー アクシオム エルエルシー | Ｋｒａｓ発現を調節するための組成物及びその使用 |
| KR20250155026A (ko) * | 2023-02-22 | 2025-10-29 | 알타미라 테라퓨틱스 아게 | 질병 치료를 위한 kras 억제용 조성물 및 방법 |
| WO2026026715A1 (zh) * | 2024-07-31 | 2026-02-05 | 前沿生物药业(南京)股份有限公司 | 一种用于抑制KRAS基因表达的siRNA及其修饰物与应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| AU776150B2 (en) | 1999-01-28 | 2004-08-26 | Medical College Of Georgia Research Institute, Inc. | Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| JP2003526367A (ja) | 2000-03-16 | 2003-09-09 | ジェネティカ インコーポレイテッド | Ｒｎａ干渉の方法とｒｎａ干渉組成物 |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| WO2003015757A1 (en) | 2001-08-16 | 2003-02-27 | The Trustees Of The University Of Pennsylvania | Synthesis and use of reagents for improved dna lipofection and/or slow release prodrug and drug therapies |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| EP1658304A4 (en) | 2002-09-28 | 2009-01-14 | Massachusetts Inst Technology | THERAPY ANTIGRIPPALE |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| WO2004048545A2 (en) | 2002-11-26 | 2004-06-10 | University Of Massachusetts | DELIVERY OF siRNAs______________________________________________ |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| AU2004257373B2 (en) | 2003-07-16 | 2011-03-24 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| CN1845993B (zh) | 2003-08-28 | 2010-06-23 | 诺瓦提斯公司 | 具有平端和3＇修饰的干扰rna双链体 |
| EP1675949A2 (en) * | 2003-10-23 | 2006-07-05 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1714970A1 (en) * | 2005-04-22 | 2006-10-25 | Universität des Saarlandes | Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |
| EP1948674A4 (en) | 2005-11-02 | 2009-02-04 | Protiva Biotherapeutics Inc | MODIFIED SIRNA MOLECULES AND APPLICATIONS THEREOF |
| ES2556128T3 (es) | 2006-03-23 | 2016-01-13 | Roche Innovation Center Copenhagen A/S | ARN interfiriente pequeño internamente segmentado |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| EP2081949B1 (en) * | 2006-09-22 | 2014-12-10 | GE Healthcare Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
| EP2121925A2 (en) * | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
| NZ580712A (en) | 2007-05-22 | 2011-12-22 | Marina Biotech Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers |
| EP2190995A2 (en) * | 2007-09-18 | 2010-06-02 | Intradigm Corporation | Compositions comprising k-ras sirna and methods of use |
| WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
| US9006191B2 (en) | 2007-12-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering RNA |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| US20110218334A1 (en) * | 2008-07-11 | 2011-09-08 | Alnylam Pharmaceuticals, Inc. | PHOSPHOROTHIOATE OLIGONUCLEOTIDES AND NON-NUCLEOSIDIC PHOSPHOROTHIOATES AS DELIVERY AGENTS FOR iRNA AGENTS |
| JP6010458B2 (ja) * | 2009-04-03 | 2016-10-19 | ダイセルナ ファーマシューティカルズ， インコーポレイテッドＤｉｃｅｒｎａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物 |
| WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| WO2011110671A2 (en) * | 2010-03-12 | 2011-09-15 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pharmaceutical composition for the treatment of chlamydial infection |
-
2013
- 2013-04-30 CN CN201380035099.2A patent/CN104583406A/zh active Pending
- 2013-04-30 CA CA2872304A patent/CA2872304C/en active Active
- 2013-04-30 EP EP13721578.6A patent/EP2844757A2/en not_active Withdrawn
- 2013-04-30 EP EP20178501.1A patent/EP3736333A1/en active Pending
- 2013-04-30 AU AU2013256471A patent/AU2013256471A1/en not_active Abandoned
- 2013-04-30 US US14/397,815 patent/US20150238515A1/en not_active Abandoned
- 2013-04-30 MX MX2014013367A patent/MX2014013367A/es unknown
- 2013-04-30 CA CA3173610A patent/CA3173610A1/en active Pending
- 2013-04-30 JP JP2015510380A patent/JP2015517466A/ja active Pending
- 2013-04-30 EP EP17187348.2A patent/EP3272868A1/en not_active Ceased
- 2013-04-30 HK HK15106884.9A patent/HK1206387A1/xx unknown
- 2013-04-30 KR KR1020147033421A patent/KR20150004414A/ko not_active Withdrawn
- 2013-04-30 EA EA201492004A patent/EA201492004A1/ru unknown
- 2013-04-30 WO PCT/US2013/038847 patent/WO2013166004A2/en not_active Ceased
- 2013-04-30 CN CN201811456141.9A patent/CN109481455A/zh active Pending
- 2013-04-30 BR BR112014027337A patent/BR112014027337A2/pt not_active IP Right Cessation
-
2016
- 2016-07-11 AU AU2016204832A patent/AU2016204832A1/en not_active Abandoned
- 2016-09-07 US US15/258,042 patent/US20180153919A1/en not_active Abandoned
-
2017
- 2017-11-14 AU AU2017261481A patent/AU2017261481A1/en not_active Abandoned
-
2020
- 2020-01-14 AU AU2020200247A patent/AU2020200247A1/en not_active Abandoned
-
2022
- 2022-05-04 AU AU2022202991A patent/AU2022202991A1/en not_active Abandoned
-
2024
- 2024-11-21 US US18/954,771 patent/US20260069625A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013256471A1 (en) | 2014-11-13 |
| CA2872304C (en) | 2022-12-06 |
| JP2015517466A (ja) | 2015-06-22 |
| US20180153919A1 (en) | 2018-06-07 |
| CN104583406A (zh) | 2015-04-29 |
| WO2013166004A2 (en) | 2013-11-07 |
| US20260069625A1 (en) | 2026-03-12 |
| CA3173610A1 (en) | 2013-11-07 |
| KR20150004414A (ko) | 2015-01-12 |
| BR112014027337A2 (pt) | 2017-07-18 |
| WO2013166004A3 (en) | 2014-01-03 |
| AU2022202991A1 (en) | 2022-05-26 |
| EP2844757A2 (en) | 2015-03-11 |
| AU2016204832A1 (en) | 2016-07-28 |
| EP3736333A1 (en) | 2020-11-11 |
| US20150238515A1 (en) | 2015-08-27 |
| HK1206387A1 (en) | 2016-01-08 |
| CA2872304A1 (en) | 2013-11-07 |
| AU2020200247A1 (en) | 2020-02-06 |
| CN109481455A (zh) | 2019-03-19 |
| EP3272868A1 (en) | 2018-01-24 |
| AU2017261481A1 (en) | 2017-11-30 |
| EA201492004A1 (ru) | 2015-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2013166004A3 (en) | Organic compositions to treat kras-related diseases | |
| NZ731797A (en) | Dna-pk inhibitors | |
| MX377405B (es) | Compuestos para el tratamiento de cáncer. | |
| MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
| UA111604C2 (uk) | ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ | |
| MX2016007311A (es) | Metodos para tratar canceres. | |
| NZ705910A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| MX2011012584A (es) | Benzoxazepinas como inhibidores de pi3k/m tor, metodos para su uso y fabricación. | |
| MX2013004761A (es) | Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas. | |
| ZA201103321B (en) | Use of anti-vegf antibody in combination with chemotherapy for treating breast cancer | |
| PH12012501836A1 (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| MX2013002155A (es) | Compuestos para el tratamiento de cancer. | |
| MX377618B (es) | Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. | |
| PH12018502569A1 (en) | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer | |
| NZ726365A (en) | Combinations for treating cancers | |
| NZ726671A (en) | Compounds useful as inhibitors of atr kinase and combination therapies thereof | |
| PH12013502334A1 (en) | Method for treatment of advanced solid tumors | |
| PH12015502757A1 (en) | Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor | |
| MX2014013763A (es) | Dosificacion y administracion de conjugados de scfv bi-especificos en combinacion con agentes terapeuticos anti-cancer. | |
| WO2014087240A3 (en) | Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis | |
| WO2012166463A3 (en) | Aminooxazole inhibitors of cyclin dependent kinases | |
| WO2013066485A3 (en) | Compositions and methods for treatment of metastatic cancer | |
| NZ626271A (en) | Tetrahydrofolates in combination with egfr-inhibitors | |
| PH12016502298A1 (en) | Vegfr2/ang2 compounds | |
| TN2015000544A1 (en) | Combination of a imidazopyridazine derivative and a mitotic agent for the treatment of cancer |